Mackenzie Financial
AKBA icon

Mackenzie Financial’s Akebia Therapeutics AKBA Stock Holding History

Mackenzie Financial’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-272,503
Closed -$432K – 1434
2025
Q4 		$432K Buy
272,503
+7,223
+3% +$15.1K ﹤0.01% 1262
2025
Q3 		$724K Buy
265,280
+16,678
+7% +$55.5K ﹤0.01% 1154
2025
Q2 		$905K Buy
248,602
+11,044
+5% +$30.3K ﹤0.01% 1040
2025
Q1 		$456K Buy
237,558
+102,166
+75% +$209K ﹤0.01% 1224
2024
Q4 		$257K Buy
135,392
+122,252
+930% +$212K ﹤0.01% 1446
2024
Q3 		$17.3K Sell
13,140
-16,518
-56% -$22.1K ﹤0.01% 1567
2024
Q2 		$30.3K Buy
29,658
+4,919
+20% +$6.08K ﹤0.01% 1510
2024
Q1 		$45.3K Buy
24,739
+1,580
+7% +$2.53K ﹤0.01% 1491
2023
Q4 		$28.7K Buy
23,159
+6,330
+38% +$6.46K ﹤0.01% 1475
2023
Q3 		$17.7K Sell
16,829
-10,370
-38% -$13.3K ﹤0.01% 1456
2023
Q2 		$24.5K Sell
27,199
-14,216
-34% -$13.7K ﹤0.01% 1492
2023
Q1 		$23.2K Sell
41,415
-26,718
-39% -$20.4K ﹤0.01% 1478
2022
Q4 		$39.3K Hold
68,133
– – ﹤0.01% 1372
2022
Q3 		$22K Buy
68,133
+25,341
+59% +$9.94K ﹤0.01% 1405
2022
Q2 		$15K Buy
42,792
+20,929
+96% +$8.78K ﹤0.01% 1447
2022
Q1 		$16K Buy
21,863
+583
+3% +$1.25K ﹤0.01% 1395
2021
Q4 		$48K Buy
+21,280
New +$58K ﹤0.01% 1402
2020
Q4 		– Sell
-20,800
Closed -$52K – 1038
2020
Q3 		$52K Sell
20,800
-33,534
-62% -$294K ﹤0.01% 962
2020
Q2 		$738K Sell
54,334
-47,288
-47% -$489K ﹤0.01% 731
2020
Q1 		$770K Buy
101,622
+65,202
+179% +$507K ﹤0.01% 710
2019
Q4 		$230K Buy
+36,420
New +$173K ﹤0.01% 1006

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Mackenzie Financial's AKBA Position: Q1 2026 in Review

Mackenzie Financial sold out of Akebia Therapeutics (AKBA) in Q1 2026, closing a stake of 272,503 shares — an estimated $432K sold.

Mackenzie Financial first reported a position in AKBA in Q4 2019 and held it in 21 quarters. The position peaked at $905K in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Mackenzie Financial reported no remaining Akebia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Mackenzie Financial sold 272,503 Akebia Therapeutics shares in Q1 2026, an estimated $432K.
  • Mackenzie Financial first reported a position in Akebia Therapeutics in Q4 2019 and held it in 21 quarters.
  • Mackenzie Financial's Akebia Therapeutics position peaked at $905K in Q2 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.